Videos

Here are the top 5 biosimilar articles for the week of March 20, 2023.

Here are the top 5 biosimilar articles for the week of March 13, 2023.

Better familiarity with biosimilars is enabling government agencies to reevaluate their approval requirements and encouraging smaller manufacturers to invest in biosimilar development, said Michael Kleinrock, lead research director for the IQVIA Institute for Human Data Science.

Here are the top 5 biosimilar articles for the week of March 6, 2023.

Here are the top 5 biosimilar articles for the week of February 27, 2023.

Here are the top 5 biosimilar articles for the week of February 20, 2023.

Here are the top 5 biosimilar articles for the week of February 13, 2023.

Adalimumab and ustekinumab biosimilars aren't the only factors that will drive biosimilar adoption and savings through 2023, according to Michael Kleinrock, lead research director for the IQVIA Institute for Human Data Science.

Here are the top 5 biosimilar articles for the week of February 6, 2023.

Here are the top 5 biosimilar articles for the week of January 30, 2023.

Here are the top 5 biosimilar articles for the week of January 23, 2023.

Here are the top 5 biosimilar articles for the week of January 16, 2023.

Here are the top 5 biosimilar articles for the week of January 9, 2023.

Ian Henshaw, senior vice president and global head of biosimilars at Biogen, shares his thoughts on whether clinical efficacy and switching studies to establish biosimilar safety are necessary, a hotly debated topic in the biosimilars industry.

Here are the top 5 biosimilar articles for the week of December 19, 2022.

Ian Henshaw, senior vice president and global head of biosimilars at Biogen, describes the importance of awareness campaigns like the International Generic and Biosimilar Medicines Association's Global Biosimilars Week and how these initiatives can be leveraged to improve biosimilar adoption and acceptance.

Here are the top 5 biosimilar articles for the week of December 12, 2022.

Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, tackles how stakeholders can collaborate and utilize market data to effectively boost biosimilar uptake.

Here are the top 5 biosimilar articles for the week of December 5, 2022.

John Gabrielson, senior vice president at JSR Life Sciences and head of Similis Bio, talked about the challenges associated with launching a business venture like Similis Bio and how Similis Bio's business model differs from other biosimilar developers and their spin-offs.

Here are the top 5 biosimilar articles for the week of November 28, 2022.

Here are the top 5 biosimilar articles for the week of November 21, 2022.

Technology utilizing electronic medical records pathways can be useful for practices struggling to manage multiple biosimilars for the same reference product, according to Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute.

Here are the top 5 biosimilar articles for the week of November 14, 2022.

Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, describes how local health policy initiatives can help providers and patients feel more comfortable with the idea of interchangeable biosimilars.

A moderated digital open forum facilitated an interactive discussion among health care professionals, health system executives, health care payers, and health policy influencers about promise and the barriers to the expanded use of biosimilars in ophthalmic applications.

Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, offers advice to health systems on how they can incorporate some of Emory Healthcare's strategies to promote biosimilar uptake.

Here are the top 5 biosimilar articles for the week of October 17, 2022.

Nabil Saba, MD, a medical oncologist and immunotherapy specialist in the treatment of head and neck cancer at Emory Healthcare and the Winship Cancer Institute, explained how the eventual introduction of biosimilars for Opdivo (nivolumab) and Keytruda (pembrolizuamb) will help patients with head and neck cancer.

Here are the top 5 biosimilar articles for the week of October 3, 2022.